TriSalus Life Sciences
TLSI | NASDAQ
$2.27
-$0.16 (-6.58%)
At close: Nov 16, 2026, 4:00 PM ET
$2.27
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-6.58%
(1D)No price chart data available for 1D timeframe.
Rating
52.2
Fundamentals Strong
Market Sentiment Neutral
Moat Narrow
Sector Rank #236/1021 (Top 23%)
Key Statistics
Market Data
Market Cap $140.06M
1D Range
2.17 2.57
52W Range
2.17 7.50
Valuation (TTM)
PE -4.63
PB 205.97
EV/EBITDA -6.71
Valuation (NTM)
Forward PE 83.33
Forward PEG 0.07
Price Target $12.00
Cash Flow
FCF Yield -22.4%
SBC Adj. FCF Yield -31.4%
SBC Impact -40.2%
Margins
Gross Margin 86.5%
Operating Margin -63.0%
FCF Margin -67.6%
Growth (CAGR)
Revenue 3Y | 5Y 42.5% |
33.1%
Dil EPS 3Y | 5Y 55.7% |
4.4%
FCF 3Y | 5Y 20.8% |
13.5%
Returns
ROA -45.6%
ROE 759.7%
ROIC -65.2%
Financial Health
Net Cash
$8.69M
Current Ratio 4.22
Interest Coverage -4.92
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver an...
Sector Healthcare
Industry Medical - Devices
Employees 102
IPO Date Feb 8, 2021
Website trisaluslifesci.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 10, 2026
EPS
-$0.15
Miss -18.02%
YoY:
+84.38% REV
$12.88M
Miss -8.12%
YoY:
+11.34%Next Earnings
Mar 4, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
3
Consensus
Buy
Price Target
$12.00
Upside
+428.63%
Buy (3)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove TLSI